all report title image
  • Published In : Jun 2024
  • Code : CMI4586
  • Pages :174
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

Key Developments

  • In October 2023, C2N Diagnostics, a molecular diagnostic, introduced an advanced fluid biomarker targeting neurofibrillary "Tau" tangle pathology in Alzheimer's Disease, offering researchers a crucial tool for monitoring disease progression by detecting Tau protein abnormalities. This breakthrough test marks significant progress in understanding and tracking Alzheimer's disease.
  • In July 2023, Quanterix Corporation, a life sciences company, launched LucentAD, a blood test utilizing biomarkers to aid in diagnosing Alzheimer’s disease in individuals
  • In November 2021, Eisai Co. Ltd, a Japan-based pharmaceutical company, and Biogen Inc., a global biotechnology company, revealed plans to present findings on the examination of plasma-based biomarkers in the Phase 3 AHEAD 3-45 trial of lecanemab (BAN2401), an experimental anti-amyloid beta (Aβ) protofibril antibody for Alzheimer's disease.
  • In October 2021, Diadem, a web hosting service provider, announced the release of clinical data demonstrating that its AlzoSure biomarker test can forecast the advancement of Alzheimer's disease several years before symptoms manifest.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.